Literature DB >> 6981473

The complement fixing properties and class distribution of rheumatoid factors (antiglobulins) in rheumatoid arthritis and other diseases.

R E March, J S Reeback, E J Holborow, V E Jones, R K Jacoby.   

Abstract

The MRSPAH (mixed reverse solid-phase passive antiglobulin haemadherence) test for antiglobulins (Agbs) of IgA, IgG and IgM classes has been quantified and also modified to measure their C3 fixing activity. An alternative ELISA technique is also described. Levels of all Agbs and their C3 fixing activity were significantly raised in established rheumatoid arthritis (RA) patients, early RA patients and established SLE patients. Ankylosing spondylitis (AS) patients had normal levels of Agbs and C3 fixation. Patients with infectious mononucleosis (IM) had high levels of all Agbs, but these did not fix complement. Thus, C3 fixing activity of Agbs is heterogeneous and raised levels are associated with the presence of joint disease. Isolated IgA, IgG and IgM fractions showed examples of Agbs which fixed C3. The proportion of C3 fixed per unit weight of Agbs was no greater in 'hidden' Agbs from serum and synovial fluids (SFs) than in untreated serum, and Agbs in SF do not fix more C3 than in serum. We conclude that the C3 fixing activity of Agbs is not directly related to affinity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981473      PMCID: PMC1536631     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  8 in total

1.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

2.  A study of complement fixation by rheumatoid factor using a haemolytic assay system.

Authors:  M M Taylor-Upsahl; P M Johnson; O J Mellbye; J B Natvig
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

3.  Complement-fixing intracellular complexes of IgG rheumatoid factor in rheumatoid plasma cells.

Authors:  E Munthe; J B Natvig
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

4.  Periodate or glutaraldehyde for preparing peroxidase conjugates?

Authors:  D M Boorsma; J G Streefkerk
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

5.  Immune complexes in early arthritis. L Detection of immune complexes before rheumatoid arthritis is definite.

Authors:  V E Jones; R K Jacoby; T Wallington; P Holt
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

6.  Metabolism of C4 and factor B in rheumatoid arthritis. Relation to rheumatoid factor.

Authors:  R A Kaplan; J G Curd; D H Deheer; D A Carson; M K Pangburn; H J Müller-Eberhard; J H Vaughan
Journal:  Arthritis Rheum       Date:  1980-08

7.  MRSPAH: a simple microtitre plate test for rheumatoid factors of different classes.

Authors:  R E March; J S Reeback; E J Holborow; R R Coombs
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

Review 8.  Rheumatoid factor: its nature, specificity, and production in rheumatoid arthritis.

Authors:  P M Johnson; W P Faulk
Journal:  Clin Immunol Immunopathol       Date:  1976-11
  8 in total
  6 in total

1.  The specificity of human autoantibodies to IgG: the development of methodology for measuring the specificity of antiglobulin isotypes in rheumatoid and normal sera.

Authors:  R E March; V R Winrow; E J Holborow
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

2.  Self-perpetuating mechanisms of immunoglobulin G aggregation in rheumatoid inflammation.

Authors:  J Lunec; D R Blake; S J McCleary; S Brailsford; P A Bacon
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

3.  Characterisation of the size and composition of circulating immune complexes in patients with rheumatoid arthritis.

Authors:  R A Mageed; J R Kirwan; P W Thompson; D A McCarthy; E J Holborow
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

4.  Enzyme immunoassay of complement-binding rheumatoid factors.

Authors:  A M Teppo; C P Maury
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

5.  Plasmodium falciparum products enhance human lymphocyte transformation by Epstein-Barr virus.

Authors:  P K Kataaha; C A Facer; E J Holborow
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

6.  Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases.

Authors:  R Klein; B Maisch; K Kochsiek; P A Berg
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.